Denosumab in Postmenopausal Women with Low Bone Mineral Density
Top Cited Papers
Open Access
- 23 February 2006
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 354 (8) , 821-831
- https://doi.org/10.1056/nejmoa044459
Abstract
Receptor activator of nuclear factor-κB ligand (RANKL) is essential for osteoclast differentiation, activation, and survival. The fully human monoclonal antibody denosumab (formerly known as AMG 162) binds RANKL with high affinity and specificity and inhibits RANKL action.Keywords
This publication has 12 references indexed in Scilit:
- Compliance with drug therapies for the treatment and prevention of osteoporosisMaturitas, 2004
- A Single-Dose Placebo-Controlled Study of AMG 162, a Fully Human Monoclonal Antibody to RANKL, in Postmenopausal WomenJournal of Bone and Mineral Research, 2004
- Osteoporosis Prevention, Diagnosis, and TherapyJAMA, 2001
- Osteoprotegerin Ligand Modulates Murine Osteoclast Survival in Vitro and in VivoThe American Journal of Pathology, 2000
- The Ligand for Osteoprotegerin (OPGL) Directly Activates Mature OsteoclastsThe Journal of cell biology, 1999
- Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligandProceedings of the National Academy of Sciences, 1999
- Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and ActivationCell, 1998
- Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKLProceedings of the National Academy of Sciences, 1998
- Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone DensityCell, 1997
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976